We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+49.13%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$642M
AUM Growth
+$54.9M
Cap. Flow
-$75.7M
Cap. Flow %
-11.79%
Top 10 Hldgs %
51.56%
Holding
44
New
10
Increased
11
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$25.9M
2
ESPR
Esperion Therapeutics
ESPR
+$19.4M
3
DVAX
Dynavax Technologies
DVAX
+$16.5M
4
ACLX
Arcellx
ACLX
+$16M
5
INSM icon
Insmed
INSM
+$15.4M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$76M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$31M
3
RAPT
RAPT Therapeutics
RAPT
+$27.3M
4
ALKS icon
Alkermes
ALKS
+$24.3M
5
CYTK icon
Cytokinetics
CYTK
+$23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
1
Neurogene
NGNE
$656M
$51.1M 7.97%
1,004,291
+10,062
+1% +$336K
ALPN
2
DELISTED
Alpine Immune Sciences Inc
ALPN
$44.7M 6.97%
1,128,499
-2,574,934
-70% -$76M
URGN icon
3
UroGen Pharma
URGN
$1.86B
$39.3M 6.13%
2,620,545
– –
ABVX
4
Abivax
ABVX
$10.9B
$35.6M 5.55%
2,488,483
+938,483
+61% +$12.1M
EOLS icon
5
Evolus
EOLS
$385M
$34.3M 5.35%
2,450,000
+450,000
+23% +$5.85M
PLRX icon
6
Pliant Therapeutics
PLRX
$64.4M
$27.6M 4.3%
1,851,864
+28,680
+2% +$473K
APGE icon
7
Apogee Therapeutics
APGE
$10.1B
$26.6M 4.14%
400,000
– –
JBIO
8
Jade Biosciences
JBIO
$1.2B
$26.2M 4.09%
25,363
-4,285
-14% -$3.27M
VRDN icon
9
Viridian Therapeutics
VRDN
$2.09B
$23.4M 3.64%
+1,335,000
New +$25.9M
ANAB icon
10
AnaptysBio
ANAB
$1.58B
$22M 3.43%
976,981
– –
ESPR
11
DELISTED
Esperion Therapeutics
ESPR
$21.4M 3.34%
+8,000,000
New +$19.4M
INSM icon
12
Insmed
INSM
$21.4B
$21M 3.28%
775,585
+549,673
+243% +$15.4M
ACLX
13
DELISTED
Arcellx
ACLX
$20.9M 3.25%
300,000
+251,736
+522% +$16M
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.06B
$19.6M 3.06%
456,148
-143,852
-24% -$6.62M
DFTX
15
Definium Therapeutics
DFTX
$5.78B
$18.8M 2.93%
+2,000,000
New +$11.4M
DNTH icon
16
Dianthus Therapeutics
DNTH
$5.84B
$18.8M 2.92%
+625,000
New +$13.6M
OTLK icon
17
Outlook Therapeutics
OTLK
$183M
$17.7M 2.75%
+1,480,000
New +$12M
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$17.6M 2.75%
1,495,500
+215,000
+17% +$2.75M
OCUL icon
19
Ocular Therapeutix
OCUL
$1.79B
$15.7M 2.45%
1,728,723
+1,028,723
+147% +$7.3M
DVAX
20
DELISTED
Dynavax Technologies
DVAX
$15.7M 2.45%
+1,264,920
New +$16.5M
CYTK icon
21
Cytokinetics
CYTK
$10.5B
$14.2M 2.21%
202,202
-297,798
-60% -$23M
OPTN
22
DELISTED
OptiNose
OPTN
$12.8M 2%
585,755
-3,574
-0.6% -$79.3K
JSPR icon
23
Jasper Therapeutics
JSPR
$21M
$12M 1.86%
+407,550
New +$7.24M
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.4M 1.62%
150,000
+39,393
+36% +$2.71M
MRUS
25
DELISTED
Merus
MRUS
$10.1M 1.57%
223,288
+203,288
+1,016% +$8.24M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Great Point Partners held 44 positions worth $642M, up 9.4% from $587M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners withdrew a net $75.7M in Q1 2024, closing 9 positions and reducing 8 holdings. Its most notable exit was Ultragenyx Pharmaceutical, an estimated $31M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Great Point Partners opened a new position in Viridian Therapeutics worth $23.4M.

  • Great Point Partners's largest Q1 2024 buy was Viridian Therapeutics: 1,335,000 shares worth $23.4M.
  • Great Point Partners added most to Arcellx in Q1 2024, an estimated $16M increase.
  • Great Point Partners's biggest Q1 2024 reduction was Alpine Immune Sciences Inc, cutting an estimated $76M.
  • Great Point Partners fully exited Ultragenyx Pharmaceutical in Q1 2024, selling an estimated $31M.
  • Great Point Partners's ten largest holdings make up 52% of its $642M portfolio in Q1 2024.
  • Great Point Partners opened 10 new positions and closed 9 in Q1 2024.
  • Great Point Partners's portfolio value rose 9.4% quarter-over-quarter to $642M.

Based on Great Point Partners's 13F filing for Q1 2024, filed 15 May 2024.